Hatch and mail order
Executive Summary
The Pharmaceutical Care Management Association and Merck-Medco have contacted Sen. Hatch's (R-Utah) office to discuss concerns about mail order pricing aired by Hatch during a Senate Finance Committee hearing on Medicare drug coverage April 24. "I know of certain circumstances where it is significantly cheaper to get the 30-day prescription filled [at retail] than it is to order a three-month supply through a mail-order plan," Hatch said, displaying a staffer's receipts for generic tetracycline, which cost $1.45 to fill at retail and $12 for a three-month mail supply. "I'm a strong supporter of PBMs, but I also believe that these are important questions that need to be addressed"
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth